Publications by authors named "Mahesh Prahladan"
Article Synopsis
- Diagnosis of essential thrombocythaemia (ET) is difficult for patients without specific genetic mutations, prompting a study of 320 'triple-negative thrombocytosis' patients to evaluate bone marrow histology and a myeloid gene panel.
- Histology showed that 36.8% of patients had supportive findings indicating myeloproliferative neoplasm, correlating with higher platelet counts, while only 14.6% of gene tests revealed significant variants.
- The study emphasizes the importance of histology in diagnosing 'triple-negative' ET, highlighting the need for caution when relying on myeloid gene panel results and suggesting the development of specific guidelines for such cases.
MYC translocation occurs in 8-14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL-MYC/BCL2-DH/TH are largely germinal centre B-cell like subtype, but show variable clinical outcome, with IG::MYC fusion significantly associated with inferior survival. While DLBCL-MYC/BCL6-DH are variable in their cell-of-origin subtypes and clinical outcome.
View Article and Find Full Text PDFDuring the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 ≥ 30%).
View Article and Find Full Text PDF